115 related articles for article (PubMed ID: 38363069)
1. Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma.
Ou J; Zheng L; Chen Y; Fu Q; Tan L; Liang E; Huang L; Pan Y; Ke J; Chen Z; Cheng K
J Med Chem; 2024 Mar; 67(5):3321-3338. PubMed ID: 38363069
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
3. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.
Gorden KK; Qiu X; Battiste JJ; Wightman PP; Vasilakos JP; Alkan SS
J Immunol; 2006 Dec; 177(11):8164-70. PubMed ID: 17114492
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and characterization of PEGylated toll like receptor 7 ligands.
Chan M; Hayashi T; Mathewson RD; Yao S; Gray C; Tawatao RI; Kalenian K; Zhang Y; Hayashi Y; Lao FS; Cottam HB; Carson DA
Bioconjug Chem; 2011 Mar; 22(3):445-54. PubMed ID: 21338093
[TBL] [Abstract][Full Text] [Related]
5. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Structure-Activity Relationship of
Chen Z; Zhang L; Yang J; Zheng L; Hu F; Duan S; Nandakumar KS; Liu S; Yin H; Cheng K
J Med Chem; 2021 Jun; 64(11):7371-7389. PubMed ID: 34029463
[TBL] [Abstract][Full Text] [Related]
7. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.
Hayashi T; Chan M; Norton JT; Wu CC; Yao S; Cottam HB; Tawatao RI; Corr M; Carson DA; Daniels GA
Melanoma Res; 2011 Feb; 21(1):66-75. PubMed ID: 21030882
[TBL] [Abstract][Full Text] [Related]
8. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
9. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus).
Zhou ZX; Sun L
Dev Comp Immunol; 2015 Mar; 49(1):113-20. PubMed ID: 25475963
[TBL] [Abstract][Full Text] [Related]
10. Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity.
Gadd AJ; Greco F; Cobb AJ; Edwards AD
Bioconjug Chem; 2015 Aug; 26(8):1743-52. PubMed ID: 26133029
[TBL] [Abstract][Full Text] [Related]
11. DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects.
Ota Y; Nagai Y; Hirose Y; Hori S; Koga-Yamakawa E; Eguchi K; Sumida K; Murata M; Umehara H; Yamamoto S
Front Immunol; 2023; 14():1055671. PubMed ID: 36793737
[TBL] [Abstract][Full Text] [Related]
12. Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity.
Ren S; Wang X; Jin G
Int J Biol Sci; 2022; 18(1):166-179. PubMed ID: 34975325
[TBL] [Abstract][Full Text] [Related]
13. The novel selective TLR7 agonist GY101 suppresses colon cancer growth by stimulating immune cells.
Ren SM; Chang JB; Liu RQ; Jin GY
Eur J Pharmacol; 2024 Mar; 967():176383. PubMed ID: 38311281
[TBL] [Abstract][Full Text] [Related]
14. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
15. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
Singh M; Khong H; Dai Z; Huang XF; Wargo JA; Cooper ZA; Vasilakos JP; Hwu P; Overwijk WW
J Immunol; 2014 Nov; 193(9):4722-31. PubMed ID: 25252955
[TBL] [Abstract][Full Text] [Related]
16. Deoxyguanosine is a TLR7 agonist.
Davenne T; Bridgeman A; Rigby RE; Rehwinkel J
Eur J Immunol; 2020 Jan; 50(1):56-62. PubMed ID: 31608988
[TBL] [Abstract][Full Text] [Related]
17. Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives.
Bazin HG; Li Y; Khalaf JK; Mwakwari S; Livesay MT; Evans JT; Johnson DA
Bioorg Med Chem Lett; 2015 Mar; 25(6):1318-23. PubMed ID: 25698055
[TBL] [Abstract][Full Text] [Related]
18. New TLR7 agonists with improved humoral and cellular immune responses.
Upchurch KC; Boquín JR; Yin W; Xue Y; Joo H; Kane RR; Oh S
Immunol Lett; 2015 Nov; 168(1):89-97. PubMed ID: 26381186
[TBL] [Abstract][Full Text] [Related]
19. MEK1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling.
Yang L; Ding JL
Front Immunol; 2019; 10():2020. PubMed ID: 31507609
[TBL] [Abstract][Full Text] [Related]
20. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
Huang SW; Chen YJ; Wang ST; Ho LW; Kao JK; Narita M; Takahashi M; Wu CY; Cheng HY; Shieh JJ
J Dermatol Sci; 2016 Oct; 84(1):59-70. PubMed ID: 27449383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
